Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 755

1.

Prediagnostic prostate-specific antigen velocity and probability of detecting high-grade prostate cancer.

Krejcarek SC, Chen MH, Renshaw AA, Loffredo M, Sussman B, D'Amico AV.

Urology. 2007 Mar;69(3):515-9.

PMID:
17382156
2.

Perineural invasion is associated with increased relapse after external beam radiotherapy for men with low-risk prostate cancer and may be a marker for occult, high-grade cancer.

Beard CJ, Chen MH, Cote K, Loffredo M, Renshaw AA, Hurwitz M, D'Amico AV.

Int J Radiat Oncol Biol Phys. 2004 Jan 1;58(1):19-24.

PMID:
14697416
3.

Predicting recurrence after radical prostatectomy for patients with high risk prostate cancer.

Grossfeld GD, Latini DM, Lubeck DP, Mehta SS, Carroll PR.

J Urol. 2003 Jan;169(1):157-63.

PMID:
12478126
4.

Prostate-specific antigen velocity and the detection of gleason score 7 to 10 prostate cancer.

Punglia RS, Cullen J, McLeod DG, Chen Y, D'Amico AV.

Cancer. 2007 Nov 1;110(9):1973-8.

5.

Gleason Pattern 5 prostate cancer: further stratification of patients with high-risk disease and implications for future randomized trials.

Nanda A, Chen MH, Renshaw AA, D'Amico AV.

Int J Radiat Oncol Biol Phys. 2009 Aug 1;74(5):1419-23. doi: 10.1016/j.ijrobp.2008.10.027. Epub 2009 Jan 7.

PMID:
19131185
6.

Adjuvant radiotherapy in prostate cancer: predictors of prostate-specific antigen recurrence from the CaPSURE database.

Macdonald OK, D'Amico AV, Sadetsky N, Shrieve DC, Carroll PR.

Urology. 2007 Jul;70(1):106-10.

PMID:
17656218
7.
8.

Prostate-specific antigen velocity and prostate cancer gleason grade and stage.

Pinsky PF, Andriole G, Crawford ED, Chia D, Kramer BS, Grubb R, Greenlee R, Gohagan JK.

Cancer. 2007 Apr 15;109(8):1689-95.

9.

Stage T1c prostate cancer: a heterogeneous category with widely varying prognosis.

Hung AY, Levy L, Kuban DA.

Cancer J. 2002 Nov-Dec;8(6):440-4.

PMID:
12500852
10.

Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.

Kupelian P, Thames H, Levy L, Horwitz E, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A, Kuban D.

Int J Radiat Oncol Biol Phys. 2005 Nov 1;63(3):795-9. Epub 2005 May 31.

PMID:
15925452
11.

Lack of association of prostate carcinoma nuclear grading with prostate specific antigen recurrence after radical prostatectomy.

Zhou M, Hayasaka S, Taylor JM, Shah R, Proverbs-Singh T, Manley S, Rubin MA.

J Urol. 2001 Dec;166(6):2193-7.

PMID:
11696734
12.

Clinical utility of endorectal MRI in determining PSA outcome for patients with biopsy Gleason score 7, PSA <or=10, and clinically localized prostate cancer.

Cheng GC, Chen MH, Whittington R, Malkowicz SB, Schnall MD, Tomaszewski JE, D'Amico AV.

Int J Radiat Oncol Biol Phys. 2003 Jan 1;55(1):64-70.

PMID:
12504037
13.

Optimizing patient selection for dose escalation techniques using the prostate-specific antigen level, biopsy gleason score, and clinical T-stage.

D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Renshaw AA, Tomaszewski JE, Richie JP, Wein A.

Int J Radiat Oncol Biol Phys. 1999 Dec 1;45(5):1227-33.

PMID:
10613317
15.

Predictors of first repeat biopsy cancer detection with suspected local stage prostate cancer.

Fowler JE Jr, Bigler SA, Miles D, Yalkut DA.

J Urol. 2000 Mar;163(3):813-8.

PMID:
10687983
16.

The impact of primary Gleason grade on biochemical outcome following brachytherapy for hormone-naive Gleason score 7 prostate cancer.

Merrick GS, Butler WM, Wallner KE, Galbreath RW, Allen ZA, Adamovich E.

Cancer J. 2005 May-Jun;11(3):234-40.

PMID:
16053667
17.

Pretreatment predictors of time to cancer specific death after prostate specific antigen failure.

D'Amico AV, Cote K, Loffredo M, Renshaw AA, Chen MH.

J Urol. 2003 Apr;169(4):1320-4.

PMID:
12629352
18.
19.
20.

Supplemental Content

Support Center